FLOW: semaglutide protected the kidney in type 2 diabetes with kidney disease

The risk of the combined kidney and cardiovascular outcome was 24% lower than with placebo.

FLOW randomly assigned 3,533 people with type 2 diabetes and high-risk chronic kidney disease to semaglutide or placebo on top of usual care. Median follow-up was 3.4 years.

The primary outcome combined kidney failure, a drop of at least 50% in glomerular filtration rate, and kidney or cardiovascular death. Its risk was 24% lower with semaglutide. The trial was stopped early for efficacy.

In three points

3,533 participants with type 2 diabetes and kidney disease
24% lower risk of the kidney and cardiovascular outcome
Median follow-up of 3.4 years

Compounds mentioned

Semaglutide

Original source: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
PubMed · New England Journal of Medicine

Plain-language summary by SYNTRA LABS based on the original publication and checked against its source. It is not medical advice or a recommendation for use. SYNTRA LABS compounds are for research use only and not for human consumption.